KALA vs SGHT vs LNTH vs NVCR

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -3. 1% for Sight Sciences, Inc. (SGHT). Lantheus Holdings, Inc. (LNTH) offers the better valuation at 26. 7x trailing P/E (17. 7x forward), making it the more compelling value choice. Analysts rate KALA BIO, Inc. (KALA) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +314. 2%, compared to -100. 0% for KALA BIO, Inc. (KALA). Over 10 years, the gap is even starker: LNTH returned +42. 9% versus KALA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.

(LNTH) is the lower-risk stock at 0. 45β versus Sight Sciences, Inc. 's 2. 41β — meaning SGHT is approximately 429% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 3% for KALA BIO, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -3. 1% for Sight Sciences, Inc. (SGHT). On earnings-per-share growth, the picture is similar: KALA BIO, Inc. grew EPS 59. 8% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -141. 1% for KALA BIO, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -150. 6% for KALA. At the gross margin level — before operating expenses — SGHT leads at 86. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for KALA: 21861.

5% to $18. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lantheus Holdings, Inc.

(LNTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45)). KALA BIO, Inc. (KALA) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LNTH: +42. 9%, KALA: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.